Your browser does not support JavaScript!

Advancements in Targeted Cancer Therapies: ADCs, PROTACs, and Combination Strategies Transforming Oncology in 2025

General Report May 5, 2025
goover

TABLE OF CONTENTS

  1. Summary
  2. PROTAC-based Cancer Therapeutics
  3. Next-Generation ADC Platforms
  4. Synergistic Combination Approaches in Oncology
  5. Biomarker-Driven Personalization and Imaging Advances
  6. Market Dynamics and Future Outlook
  7. Conclusion

1. Summary

  • As of early 2025, the oncology sector is undergoing a transformative phase marked by a profusion of innovations in targeted cancer therapies, including Proteolysis Targeting Chimeras (PROTACs), groundbreaking antibody-drug conjugates (ADCs), and novel combination treatment strategies. Noteworthy advancements in PROTAC technologies are evidenced by the preclinical success of candidates such as ARV-393, which has showcased the potential to degrade the B-cell lymphoma 6 (BCL6) protein, pivotal in combating aggressive B-cell lymphomas. The promising efficacy demonstrated by ARV-393 in ongoing studies highlights a significant shift in the treatment paradigms for patients facing relapsed and refractory forms of non-Hodgkin lymphoma.

  • In the ADC domain, ONA-255 is gaining recognition as a first-in-class construct, representing a major stride in the treatment of solid tumors. Its targeted approach, coupled with rigorous clinical evaluations, promises to redefine therapeutic strategies in oncology. The ADC market, expected to grow dramatically to approximately $227 billion, reflects the increasing confidence in these technologies, with collaborations and innovations from leading pharmaceutical companies driving an unprecedented pipeline of therapies aimed at improving patient outcomes.

  • Importantly, the integration of ADCs with immunotherapies, exemplified by emerging combinations like pepinemab with immune checkpoint inhibitors, illustrates a strategic approach to enhance therapeutic efficacy and overcome tumor resistance mechanisms. These developments underscore the critical role of biomarkers and precision medicine, guiding treatment personalization and supporting clinical decision-making. Advances in diagnostic methodologies, particularly in liquid biopsies and genomic profiling, further empower oncologists to tailor interventions based on individual patient profiles, highlighting a paradigm shift towards more effective and personalized oncology care. The sustained momentum in this field is reflected in robust market forecasts, projecting continued growth in biopharmaceutical sectors well into 2035 and beyond.

2. PROTAC-based Cancer Therapeutics

  • 2-1. Mechanism and promise of PROTAC degraders

  • Proteolysis Targeting Chimeras (PROTACs) represent a novel approach in cancer therapeutics that harnesses the body's ubiquitin-proteasome system to induce the degradation of disease-causing proteins. Unlike traditional small-molecule inhibitors that merely block the action of a protein, PROTACs bind to their target while simultaneously recruiting an E3 ligase, leading to ubiquitination and subsequent proteasomal degradation of the target. This unique mechanism not only addresses the challenge of 'undruggable' proteins but can also extend the therapeutic effect beyond the limits of conventional drugs, thanks to their catalytic nature. As a result, PROTACs hold great promise in oncology, particularly for tumors that exhibit resistance to existing treatments due to their ability to target multiple pathways and proteins associated with cancer progression and survival.

  • 2-2. Preclinical data for ARV-393 targeting BCL6

  • ARV-393, a PROTAC designed to degrade the B-cell lymphoma 6 (BCL6) protein, has demonstrated promising preclinical results. BCL6 is a transcriptional repressor that plays a pivotal role in the development of several aggressive B-cell lymphomas, rendering it a crucial target for therapeutic intervention. Recent preclinical studies indicated that ARV-393, when combined with various standard lymphoma therapies, could enhance tumor regression in models of diffuse large B-cell lymphoma. This combination strategy is set to be further detailed at the upcoming American Association for Cancer Research (AACR) Annual Meeting, with presentations scheduled for late April 2025. These findings underscore the potential of targeting BCL6 through PROTAC technology, presenting a novel therapeutic avenue for relapsed and refractory non-Hodgkin lymphoma patients.

  • 2-3. Emerging degrader-antibody conjugates in oncology

  • The development of degrader-antibody conjugates (DACs), which combine the advantages of PROTACs with antibody-drug conjugate technology, marks a significant innovation in the field of oncology. These novel constructs aim to improve upon traditional antibody-drug conjugates by employing a PROTAC payload that triggers the degradation of multiple target proteins, rather than simply inhibiting them. This approach could lead to enhanced efficacy by potentially reducing drug resistance and improving the specificity of treatments tailored for various cancers. Current analytics suggest that South Korea and China are emerging as key players in DAC development, with multiple assets currently in various stages of clinical and preclinical trials. Notably, the first-in-class HER2-targeted Antibody neoDegrader Conjugate (AnDC™), ORM-5029, shows promise in effectively targeting and degrading HER2-expressing cells. These advancements could pave the way for more effective treatment options in the fight against cancer.

3. Next-Generation ADC Platforms

  • 3-1. ONA-255: first-in-class ADC breakthrough

  • ONA-255 represents a significant advancement in the field of targeted cancer therapy, emerging as a first-in-class antibody-drug conjugate (ADC) tailored for the treatment of solid tumors. Developed through a partnership between Reveal Genomics and Ona Therapeutics, this novel ADC is distinguished by its ability to target a unique site found within various malignancies, which could potentially redefine treatment pathways. The key contributors, Dr. Aleix Prat and Dr. Roger Gomis, have been instrumental in generating preclinical data that showcases the efficacy of ONA-255, providing a strong foundation for its ongoing clinical evaluation.

  • The therapeutic promise of ONA-255 is bolstered by an integrative approach that combines advanced diagnostics with robust molecular profiling. This partnership intends to analyze tumor and blood samples collected during Phase I-II clinical trials to establish an in-depth understanding of biomarkers that may predict therapeutic response. Such meticulous biological exploration is designed to optimize patient enrollment strategies in clinical trials, targeting those most likely to benefit from this targeted therapy.

  • Support from institutional bodies, such as the Spanish Ministry of Science and Innovation, highlights the credibility and potential impact ONA-255 may have on oncology, indicating a broad consensus within the scientific community regarding its innovative approach. Moreover, the anticipated trajectory of ONA-255 encapsulates a pivotal step towards a future where cancer treatment aligns more closely with precision medicine.

  • 3-2. Global ADC innovation pipeline and deal activity

  • The ADC sector is currently experiencing an unprecedented wave of innovation, underscored by a plethora of emerging therapies and substantial deal activity. Recent analyses show that over 1, 172 drugs have been evaluated within clinical trials, primarily targeting oncology, which constitutes 94% of the ADC landscape. Pfizer and Daiichi Sankyo have emerged as dominant entities in leading clinical trials, drawing on extensive pipelines and significant financial backing.

  • In terms of market dynamics, a report published on April 18, 2025, reveals that the global ADC market is poised for remarkable growth, with transactions accumulating to approximately $227 billion. This financial boom is anticipated to drive FDA approvals, enhance collaboration agreements, and expedite partnerships among key pharmaceutical players. The merging of traditional pharmaceutical companies with innovative biotech firms is fostering an environment rich in research and development, pushing the boundaries of what is feasible within cancer therapeutics.

  • As pioneers in ADCs expand their portfolios, the filtrating of strategic investments through mergers and acquisitions indicates a robust commitment to advancing technologies. The sustained interest in ADCs is a testament to their effectiveness at precisely targeting cancer cells and minimizing collateral damage to healthy tissues, enhancing the therapeutic landscape for patients battling various cancers.

  • 3-3. Market dynamics driving ADC investment

  • Market forces are increasingly influencing the development and investment landscape for ADC technologies, which stand at the intersection of innovation and patient care. As healthcare dynamics shift towards personalized medicine, pharmaceutical companies are prioritizing investments in ADCs due to their high specificity and reduced side effects. With 37% of patent filings in the ADC space attributed to major players like Roche and Seagen, the competitive landscape is ripe with opportunity for novel developments.

  • The ADC market has seen a resurgence following a lull from 2020 to 2022, with a notable rebound in partnerships and deal-making activity in 2023. This has been a driving force behind the rapid advancements being made in ADC technologies. Emerging markets, particularly in regions like China, are increasingly participating in this growth, with local companies developing competitive ADC platforms aimed at both domestic and global markets.

  • Furthermore, as the landscape evolves, the integration of genomic data, computational biology, and advances in biomarker identification are expected to significantly enhance ADC efficacy and precision. This evolution suggests a future where ADCs will not only provide targeted therapies but will also evolve in tandem with the advancements in personalized oncology, ensuring that treatment protocols are as effective as possible for individual patients.

4. Synergistic Combination Approaches in Oncology

  • 4-1. Rationale for ADC-immunotherapy combinations

  • The integration of Antibody-Drug Conjugates (ADCs) with immunotherapies represents a significant strategic advancement in oncology. This synergy is grounded in the ability of ADCs to deliver cytotoxic agents directly to tumor cells while simultaneously engaging immune responses to enhance overall therapeutic effectiveness. A prominent example involves pepinemab, a Semaphorin 4D blocking antibody, which has shown promise in combining with immune checkpoint inhibitors. Recent data from Vaccinex indicates that this combination can enhance the maturation of resulting tertiary lymphoid structures (TLS) within tumors, leading to improved immune cell interactions and clinical outcomes for patients with melanoma and head and neck cancers. These findings suggest that such combination strategies can potentially transform previously cold tumors into more amenable and responsive environments for immunotherapy.

  • 4-2. Organoid platforms guiding personalized regimens

  • Organoid technology is emerging as a powerful tool in the development of personalized cancer therapies. By culturing patient-derived tumor cells in three-dimensional structures, researchers can closely mimic the tumor microenvironment, allowing for more accurate testing of various therapeutic combinations. At the recent AACR Annual Meeting, findings from UCLA highlighted the use of organoid platforms designed to evaluate drug sensitivity and personalized treatment regimens for head and neck squamous cell carcinoma (HNSCC). This innovative approach not only facilitates the identification of the most effective drug combinations tailored to an individual’s tumor profile but also enhances understanding of tumor heterogeneity, which is crucial for overcoming resistance to therapy.

  • 4-3. Clinical insights from lung cancer and melanoma studies

  • Clinical studies have illustrated the potential benefits of synergistic combination approaches in treating advanced lung cancer and melanoma. A significant study commemorated in 2025 introduced a dual-modality treatment combining bronchial arterial chemoembolization/infusion with iodine-125 brachytherapy, demonstrating substantial clinical efficacy in patients with non-small cell lung cancer (NSCLC) who had previously exhausted standard options. The data revealed impressive survival outcomes, substantially enhancing median progression-free and overall survival rates, particularly when treatment was initiated early. In parallel, the use of pepinemab in combination with immune checkpoint inhibitors has shown remarkable results in improving response rates and overall survival in melanoma patients. These insights underscore the urgency of further exploring combined modalities as a mechanism to enhance the therapeutic landscape in oncology, where conventional methods encounter limitations.

5. Biomarker-Driven Personalization and Imaging Advances

  • 5-1. Computational biomarker discovery partnerships

  • The landscape of cancer treatment continues to evolve through strategic collaborations focused on computational biomarker discovery. As of May 2025, companies like Renovaro have entered into pivotal partnerships that leverage artificial intelligence (AI) to enhance diagnostic capabilities. By collaborating with high-performance computing providers such as Nebul, Renovaro seeks to accelerate the development of diagnostic tests that can detect minimal residual disease (MRD) in lung cancer patients. This approach is significant as MRD detection is critical for preventing relapses and improving long-term patient outcomes. By harnessing AI-driven models with immense computational power, these collaborations are setting a precedent for how data-driven diagnostics can revolutionize precision medicine, potentially across various cancer types.

  • 5-2. Molecular imaging breakthroughs in precision medicine

  • Recent advancements in molecular imaging are reshaping precision medicine by enabling more refined diagnostic capabilities. According to data published on May 2, 2025, a groundbreaking positron emission tomography (PET) tracer, carbon-11 labeled HSP990 (^11C-HSP990), has been developed to visualize the expression of heat shock protein 90 (Hsp90) in the brain. This discovery is particularly relevant for early detection of Alzheimer’s disease and signifies a leap toward identifying biomarkers that can monitor disease progression with remarkable sensitivity. In oncology, innovative immuno-PET/CT tracers targeting cancer-specific markers, such as CD70 in nasopharyngeal carcinoma, are enhancing the detection accuracy of tumors, indicating a substantial shift toward more personalized and effective treatment strategies.

  • 5-3. Predictive biomarkers for targeted therapies

  • Predictive biomarkers are gaining traction as critical tools for optimizing targeted cancer therapies. For instance, a comprehensive study regarding the neoadjuvant use of axitinib in renal cell carcinoma highlights both angiogenic and immune factors that can predict patient responses. As disclosed in a publication from May 1, 2025, the research identified specific expression patterns of angiogenic genes that, alongside the tumor’s immune context, dictate therapeutic responses. This insight enables clinicians to tailor treatments based on a patient's unique biological makeup, thereby improving the likelihood of successful outcomes and minimizing the trial and error often associated with cancer therapies.

  • 5-4. Leadership shifts in clinical trial consortia

  • Changes in leadership within clinical trial organizations are set to steer new directions in cancer research and imaging integration. As of May 2025, NRG Oncology has appointed Dr. Kristin Higgins as the Chair of its Lung Cancer Committee and Dr. Karthik Sundaram as the Chair of its Imaging Committee. These appointments are not just organizational shifts; they represent a commitment to innovation in clinical trial designs that leverage advanced imaging techniques and target the latest therapeutic strategies. Dr. Sundaram’s focus on molecular imaging techniques promises to enhance the precision and applicability of trials, ensuring that cutting-edge imaging is seamlessly incorporated into trial protocols. These leadership changes illustrate a strategic alignment towards a more collaborative and multidisciplinary approach in advancing cancer care.

6. Market Dynamics and Future Outlook

  • 6-1. Genomic cancer panel and profiling market forecast 2025–2035

  • The global genomic cancer panel and profiling market is poised for significant growth between 2025 and 2035, with a projected compound annual growth rate (CAGR) of 9.67%. Several factors are driving this expansion, including rising cancer incidences and the increasing reliance on precision medicine. As of 2022, approximately 19.97 million cancer cases were reported, underlining a growing demand for early diagnosis and targeted treatment approaches facilitated by genomic panels. Key players such as Burning Rock Dx, Caris Life Sciences, and Exact Sciences are at the forefront, with strategies that include innovative product offerings and strategic partnerships, enhancing market dynamism.

  • The segmentation of the market provides insights into various components: solid tissue testing dominates diagnostics, while multi-gene panels are favored for their comprehensive genetic profiles. The clinical segment holds the largest market share, as hospitals increasingly adopt genomic testing to improve patient outcomes. Challenges, notably high testing costs, especially in developing regions, could hinder market growth. However, opportunities remain in emerging markets, where improved healthcare infrastructures are enhancing the adoption of genomic technologies.

  • 6-2. Growth trajectory of liquid biopsy diagnostics

  • The liquid biopsy market in cancer diagnostics is rapidly evolving, and it is projected to achieve a CAGR of approximately 17% by 2032. This growth is largely attributed to advancements in non-invasive testing technologies and a rising demand for early detection of cancer. As an alternative to traditional biopsies, liquid biopsies facilitate the analysis of blood and other bodily fluids for cancer biomarkers, providing real-time insights into tumor genetics and supporting personalized treatment strategies.

  • Major players such as Myriad Genetics, Exact Sciences, and Thermo Fisher Scientific are leading the market, constantly innovating and integrating new technologies like next-generation sequencing and digital PCR to enhance the effectiveness of liquid biopsies. North America remains the largest market, driven by high cancer prevalence and a strong focus on oncology research. Meanwhile, regions such as Asia-Pacific are emerging due to rising cancer incidences and improvements in diagnostic methodologies. Legislation supporting liquid biopsy innovations is also boosting adoption rates across various markets.

  • 6-3. Biopharmaceutical market expansion to 2030

  • The global biopharmaceutical market is forecasted to grow from an estimated $412.1 billion in 2024 to $698.7 billion by 2030, encompassing a CAGR of 9.2%. This expansion is fueled by rising incidences of chronic diseases, notably cancer, which demand prolonged treatment and innovative therapies. Monoclonal antibodies and gene therapies are among the drivers of this growth, as they have shown significant efficacy in treating a variety of conditions.

  • Investment in research and development and increasing healthcare expenditures, particularly in developing nations, play crucial roles in this market's dynamism. North America currently dominates the market due to advanced healthcare infrastructure and regulatory support. However, the Asia-Pacific region, projected to grow at a CAGR of 11.2%, is also becoming influential, with developments in vaccine production and drug manufacturing.

  • 6-4. Cancer diagnostics market trends and opportunities

  • The cancer diagnostics market is set to expand at a CAGR of 7-9% by 2029, driven by technological advancements and an increased emphasis on early detection methods. Innovations such as next-generation sequencing (NGS), liquid biopsy technologies, and AI integration are enhancing diagnostic accuracy and supporting personalized medicine initiatives. The market conditions are very favorable, encouraged by increasing cancer incidence rates and ongoing education about the importance of early detection.

  • While North America and Europe continue to lead the market with established healthcare systems and extensive use of advanced diagnostics, emerging economies also offer significant growth potential. These regions are enhancing healthcare infrastructure, improving access to diagnostics, and fostering collaboration with private diagnostic centers. Overall, the trend towards personalized treatment continues to necessitate advancements in cancer diagnostics, indicating a robust future for this sector.

Conclusion

  • The year 2025 stands as a watershed moment in the realm of precision oncology, where diverse therapeutic modalities coalesce to enhance treatment efficacy and patient-centric approaches. With PROTACs and novel ADCs transitioning from preclinical phases to tangible clinical applications, the landscape of cancer treatment is rapidly maturing. These advancements, coupled with strategic immunotherapy combinations, hold the potential to dismantle barriers of resistance commonly faced in oncology. As biomarker discovery and innovations in imaging technologies continue to progress, they provide invaluable tools for refining patient selection and monitoring therapeutic responses in real time.

  • The market outlook remains optimistic, with strong forecasts indicating double-digit growth in genomic testing and liquid biopsy diagnostics, signaling an upsurge in the demand for personalized treatment strategies. As investments in these areas escalate, the focus will increasingly shift toward integrated development frameworks that align innovative molecular therapies with current clinical practices. The synthesis of these strategies is poised to not only enhance the rapid delivery of effective cancer therapies but also to ensure that treatment modalities are responsive to the dynamic needs of patients. As we move forward, the horizon of oncology is brightening, characterized by collaborative efforts that promise to redefine the future of cancer care through individualized and precise treatment options.

Glossary

  • Antibody-drug conjugates (ADCs): ADCs are targeted cancer therapies that combine an antibody with a cytotoxic drug. The antibody specifically binds to cancer cells and delivers the cytotoxic agent directly, minimizing damage to surrounding healthy tissues. As of May 2025, ADCs have grown significantly, with constructs like ONA-255 showing promising results in the treatment of solid tumors.
  • PROTAC: Proteolysis Targeting Chimeras (PROTACs) are innovative therapeutics that leverage the body's protein degradation mechanism to eliminate disease-causing proteins. They bind to a target protein and recruit an E3 ligase to promote its degradation, offering a new strategy for addressing previously 'undruggable' proteins in cancer, with preclinical candidates like ARV-393 demonstrating efficacy.
  • Combination therapy: Combination therapy involves using more than one treatment approach simultaneously to enhance overall effectiveness against cancer. This strategy seeks to improve outcomes by leveraging the synergistic effects of different therapeutic modalities, such as ADCs combined with immunotherapies, to overcome resistance mechanisms in tumors.
  • Immunotherapy: Immunotherapy is a cancer treatment approach that uses the body's immune system to fight cancer. By enhancing the immune response against cancer cells, immunotherapies like checkpoint inhibitors and antibodies may lead to better patient outcomes. Recent combinations with ADCs, such as pepinemab, aim to improve efficacy in certain cancers.
  • Biomarkers: Biomarkers are measurable indicators of the severity or presence of some disease state, commonly used to determine prognosis and therapeutic responses in cancer treatments. The discovery of new biomarkers is critical for precision medicine, guiding individualized treatment plans and improving patient care in oncology.
  • BCL6: BCL6 is a transcription factor implicated in the development of certain aggressive B-cell lymphomas. As a target for cancer therapy, drugs like ARV-393 aim to degrade BCL6, offering a promising new direction in the treatment of diseases like non-Hodgkin lymphoma, particularly for patients resistant to standard treatments.
  • ONA-255: ONA-255 is a first-in-class antibody-drug conjugate (ADC) designed for the treatment of solid tumors. As of May 2025, it is undergoing clinical evaluation to confirm its efficacy and safety, representing a significant advancement in targeted cancer therapies through its unique mechanism of action.
  • Pepinemab: Pepinemab is a blocking antibody targeting Semaphorin 4D, which has shown promise in combination with immune checkpoint inhibitors to improve immune cell interactions within tumors. This approach aims to enhance the response to therapy, particularly in melanoma and head and neck cancers, reflecting a broader trend towards combining modalities for improved outcomes.
  • Liquid biopsy: Liquid biopsy involves analyzing bodily fluids, such as blood, to detect cancer-related biomarkers or circulating tumor DNA. This non-invasive method allows for real-time insights into tumor dynamics and is increasingly being integrated into personalized cancer care strategies. The market for liquid biopsies is anticipated to grow significantly by 2032.
  • Genomic testing: Genomic testing refers to testing that examines an individual's DNA to identify genetic alterations that might affect cancer treatment. It plays a crucial role in precision medicine by enabling oncologists to tailor therapies based on specific genetic profiles, thereby improving therapeutic efficacy and reducing unnecessary side effects.
  • Precision medicine: Precision medicine is an approach that customizes healthcare, with medical decisions and treatments tailored to the individual characteristics of each patient. In oncology, this concept encompasses targeted therapies and biomarker identification to optimize treatment efficacy based on a patient's unique genetic or molecular profile.

Source Documents